Novo Nordisk A/S (NVO) Shares Sold by SG Americas Securities LLC
SG Americas Securities LLC reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 32.0% during the second quarter, according to its most recent filing with the SEC. The fund owned 43,800 shares of the company’s stock after selling 20,612 shares during the period. SG Americas Securities LLC’s holdings in Novo Nordisk A/S were worth $1,879,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its position in Novo Nordisk A/S by 17.7% in the first quarter. Renaissance Technologies LLC now owns 16,409,200 shares of the company’s stock worth $562,507,000 after buying an additional 2,463,300 shares in the last quarter. Bank of America Corp DE boosted its position in Novo Nordisk A/S by 3.2% in the first quarter. Bank of America Corp DE now owns 12,102,582 shares of the company’s stock worth $414,876,000 after buying an additional 380,536 shares in the last quarter. Fisher Asset Management LLC boosted its position in Novo Nordisk A/S by 12.9% in the second quarter. Fisher Asset Management LLC now owns 11,690,997 shares of the company’s stock worth $501,427,000 after buying an additional 1,331,992 shares in the last quarter. State Street Corp boosted its position in Novo Nordisk A/S by 64,406.4% in the first quarter. State Street Corp now owns 5,593,351 shares of the company’s stock worth $191,740,000 after buying an additional 5,584,680 shares in the last quarter. Finally, Sustainable Growth Advisers LP boosted its position in Novo Nordisk A/S by 17.3% in the first quarter. Sustainable Growth Advisers LP now owns 4,068,896 shares of the company’s stock worth $139,482,000 after buying an additional 598,644 shares in the last quarter. 6.33% of the stock is currently owned by institutional investors and hedge funds.
Shares of Novo Nordisk A/S (NVO) opened at 46.13 on Friday. The stock has a market capitalization of $114.41 billion, a price-to-earnings ratio of 18.96 and a beta of 0.63. Novo Nordisk A/S has a 52-week low of $30.89 and a 52-week high of $47.32. The firm’s 50-day moving average is $43.48 and its 200 day moving average is $39.56.
The firm also recently declared an annual dividend, which will be paid on Tuesday, August 29th. Stockholders of record on Monday, August 21st will be paid a $0.336 dividend. This is an increase from Novo Nordisk A/S’s previous annual dividend of $0.33. This represents a dividend yield of 1.07%. The ex-dividend date is Friday, August 18th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 36.44%.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/08/27/novo-nordisk-as-nvo-shares-sold-by-sg-americas-securities-llc.html.
NVO has been the topic of a number of research analyst reports. Zacks Investment Research cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. BidaskClub cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Thursday, June 29th. Finally, TheStreet raised Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research note on Tuesday, May 2nd. Four analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $53.00.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Stock Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related stocks with our FREE daily email newsletter.